Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21751788 | 0.96 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL25886857 | 0.90 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL23165244 | 0.89 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL30018625 | 0.89 | DGAT1 (0.37) | DGAT1NPC1 | |
| SCHEMBL21751778 | 0.89 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL21751562 | 0.89 | DGAT1 (0.38) | DGAT1 | |
| Ammonia Solution, Strong SCHEMBL28939497 | 0.88 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL25349464 | 0.85 | DGAT1 (0.38) | DGAT1NPC1 | |
| SCHEMBL21751870 | 0.83 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL28440805 | 0.83 | DGAT1 (0.33) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2A1 | DGAT1 4452/4885NPC1 3489/4885 |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885NPC1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.